Drugs related to monoamine oxidase activity
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
26944656
DOI
10.1016/j.pnpbp.2016.02.012
PII: S0278-5846(16)30027-6
Knihovny.cz E-resources
- Keywords
- Hybrid drug, Mental disorder, Monoamine oxidase, Monoamine oxidase inhibitor, Neuroprotection,
- MeSH
- Mental Disorders drug therapy enzymology MeSH
- Monoamine Oxidase Inhibitors chemical synthesis pharmacology therapeutic use MeSH
- Humans MeSH
- Monoamine Oxidase metabolism MeSH
- Synaptic Transmission drug effects physiology MeSH
- Neurodegenerative Diseases drug therapy enzymology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Monoamine Oxidase Inhibitors MeSH
- Monoamine Oxidase MeSH
Progress in understanding the role of monoamine neurotransmission in pathophysiology of neuropsychiatric disorders was made after the discovery of the mechanisms of action of psychoactive drugs, including monoamine oxidase (MAO) inhibitors. The increase in monoamine neurotransmitter availability, decrease in hydrogen peroxide production, and neuroprotective effects evoked by MAO inhibitors represent an important approach in the development of new drugs for the treatment of mental disorders and neurodegenerative diseases. New drugs are synthesized by acting as multitarget-directed ligands, with MAO, acetylcholinesterase, and iron chelation as targets. Basic information is summarized in this paper about the drug-induced regulation of monoaminergic systems in the brain, with a focus on MAO inhibition. Desirable effects of MAO inhibition include increased availability of monoamine neurotransmitters, decreased oxidative stress, decreased formation of neurotoxins, induction of pro-survival genes and antiapoptotic factors, and improved mitochondrial functions.
References provided by Crossref.org
